Tag: efmoroctocog alfa

Successful Elocta bid should widen access to the drug in the UK

by Selina McKee | Jun 29, 2020 | News | 0

Through an agreement with the NHS and Sobi UK, people living with haemophilia A in the UK will have increased access to Elocta following a successful bid in the UK’s Haemophilia A Tender

Ireland procures Sobi therapies for all haemophilia patients

by Selina McKee | Feb 7, 2018 | News | 0

The Republic of Ireland has become the first country in Europe to switch its entire population with haemophilia A and B treated with short-acting replacement clotting factors to Swedish Orphan Biovitrum’s (Sobi) extended half-life therapies Elocta and Alprolix.